Clinical Trial Update: Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating subcutaneous ofatumumab in relapsing-remitting multiple sclerosis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ofatumumab (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2018-03-01